These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28514822)

  • 1. [Cardiovascular Effects of Antidiabetic Therapies].
    Laubner K; Seufert J
    Dtsch Med Wochenschr; 2017 May; 142(10):737-745. PubMed ID: 28514822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular safety outcomes of new antidiabetic therapies.
    LeBras MH; Barry AR; Koshman SL
    Am J Health Syst Pharm; 2017 Jul; 74(13):970-976. PubMed ID: 28483748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications.
    Eleftheriadou I; Grigoropoulou P; Liberopoulos E; Liatis S; Kokkinos A; Tentolouris N
    Curr Med Chem; 2018; 25(13):1549-1566. PubMed ID: 28554326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.
    Asleh R; Sheikh-Ahmad M; Briasoulis A; Kushwaha SS
    Heart Fail Rev; 2018 May; 23(3):445-459. PubMed ID: 29270818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
    Med Lett Drugs Ther; 2019 Feb; 61(1566):26-28. PubMed ID: 30845101
    [No Abstract]   [Full Text] [Related]  

  • 6. SAVOR-TIMI to SUSTAIN-6: a critical comparison of cardiovascular outcome trials of antidiabetic drugs.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):429-442. PubMed ID: 28121469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type 2 diabetes and cardiovascular prevention: the dogmas disputed.
    Giugliano D; Maiorino MI; Bellastella G; Esposito K
    Endocrine; 2018 May; 60(2):224-228. PubMed ID: 28895030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Outcomes of New Medications for Type 2 Diabetes.
    Trujillo JM; Wettergreen SA; Nuffer WA; Ellis SL; McDermott MT
    Diabetes Technol Ther; 2016 Dec; 18(12):749-758. PubMed ID: 27835045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidiabetic agents and cardiovascular outcomes in patients with heart diseases.
    Cheng JWM; Badreldin HA; Patel DK; Bhatt SH
    Curr Med Res Opin; 2017 Jun; 33(6):985-992. PubMed ID: 28097882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of oral antidiabetic medications in heart failure patients.
    Palazzuoli A; Ceccarelli E; Ruocco G; Nuti R
    Heart Fail Rev; 2018 May; 23(3):325-335. PubMed ID: 29359260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials.
    Bailey CJ; Marx N
    Diabetes Obes Metab; 2019 Jan; 21(1):3-14. PubMed ID: 30091169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cardiovascular outcome clinical trials in type 2 diabetes mellitus: what are the epidemiological and methodological evidence and the first evaluations to date?].
    Fiorentino TV; Sesti G
    G Ital Cardiol (Rome); 2016 Mar; 17(3 Suppl 2):24S-31. PubMed ID: 27030121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of new GLP-1 receptor agonists for type 2 diabetes.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016; 25(2):145-58. PubMed ID: 26587691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes Mellitus and Cardiovascular Disease: An Evidence-Based Review of Provincial Formulary Coverage.
    Riar SS; Fitchett D; FitzGerald J; Dehghani P
    Can J Cardiol; 2018 Oct; 34(10):1362-1364. PubMed ID: 30269833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Antidiabetic Agents and Cardiovascular Outcomes.
    Pareek M; Bhatt DL
    Curr Probl Cardiol; 2018 Mar; 43(3):111-126. PubMed ID: 28844525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes.
    Standl E; Schnell O; McGuire DK; Ceriello A; Rydén L
    Lancet Diabetes Endocrinol; 2017 May; 5(5):391-402. PubMed ID: 28131656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2015 Sep; 14():129. PubMed ID: 26415691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular pleiotropic actions of DPP-4 inhibitors: a step at the cutting edge in understanding their additional therapeutic potentials.
    Balakumar P; Dhanaraj SA
    Cell Signal; 2013 Sep; 25(9):1799-803. PubMed ID: 23707531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Type 2 diabetes treatment and cardiovascular risk: what can we learn from trials?].
    Consoli A; Febo F
    G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):20S-27. PubMed ID: 28151518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.